Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
At Vincerx Pharma, a filing with the SEC revealed that on Tuesday, Chief Executive Officer Ahmed Hamdy, M.
.
Bought 7,830 shares of VINC, for a cost of $12.77 each, for a total investment of $99,989.
So far Hamdy, M.
.
Is in the green, up about 16.5% on their buy based on today's trading high of $14.88.
Vincerx Pharma Inc is trading up about 10.5% on the day Thursday.
And on Monday, Director James A.
Geraghty purchased $91,600 worth of Fulcrum Therapeutics, purchasing 10,000 shares at a cost of $9.16 a piece.
Fulcrum Therapeutics Inc is trading up about 0.2% on the day Thursday.
Geraghty was up about 14.7% on the buy at the high point of today's trading session, with FULC trading as high as $10.51 at last check today.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider..
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider..
